-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is the most common type of dementia in the elderly
.
According to the "World Alzheimer's Disease Report 2018", there are currently about 50 million people worldwide suffering from dementia, and two-thirds of them suffer from AD
Sodium oligosaccharide (GV-971) is a kind of oligosaccharide derived from the ocean.
It is a mixture of linear and acidic oligosaccharides.
Based on the results and experience of the Phase 2 trial, Shifu Xiao and others of the Shanghai Psychiatric Center designed and completed the Phase 3 trial
.
To further evaluate the efficacy and safety of GV-971 in patients with mild to moderate AD
We conducted a phase 3 double-blind, placebo-controlled trial in patients with mild to moderate AD to evaluate the efficacy and safety of GV-971
.
Participants were randomly assigned to placebo or GV-971 (900 mg) for 36 weeks
A total of 818 participants were randomly assigned
.
408 people took GV-971 and 410 people took a placebo
After 36 weeks of treatment, the difference from baseline between the groups was -2.
15 points (95% confidence interval, -3.
The important significance of this study lies in the discovery: GV-971 has shown a significant effect in improving cognition, and has continued to improve in all observation periods of the 36-week trial
.
GV-971 is safe and well tolerated
GV-971 has shown a significant effect in improving cognition, and has continued to improve during all observation periods of the 36-week trial
Original source:
Xiao S, Chan P, Wang T, et al.
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia .
Alz Res Therapy.
2021;13(1):62.
doi:10.
1186/s13195-021-00795-7
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Leave a message here
